Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference 2021/09/09 12:30:00 Intrado Digital Media
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Randy Brenner, Chief Development and Regulatory Officer, will present at the H.C. Wainwright 23 rd Annual Global Investment (Virtual) Conference. The on-demand presentation will be available on September 13 at 7:00 a.m. ET.
Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA® (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria 2021/08/18 20:12:00 Intrado Digital Media
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for NUZYRA ® (omadacycline) for the treatment of infections caused by Nontuberculous Mycobacteria (NTM). This orphan drug designation includes NTM pulmonary disease caused by Mycobacterium abscessus complex (MABc), which is the focus of an ongoing Phase 2b study initiated by Paratek. The FDAs Office of Orphan Drug Products grants orphan status to drugs and biologics that demonstrate promise for the treatment of diseases or conditions affecting fewer than 200,000 people in the United States. Orphan drug designation provides Paratek with certain development incentives, including tax credits for qualified clinical testing, exemptions from certain FDA application fees, and potential market exclusivity, if approved. The orphan drug designation is an important regulatory milestone that further validates our efforts to investigate the utility of NUZYRA, a once-daily, broad-spectrum antibiotic currently approved for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, as a potential therapy option for patients afflicted with M. abscessus pulmonary disease, an orphan disease for which there are no approved therapies, said Randy Brenner, Chief Development and Regulatory Officer of Paratek. Earlier this year, we initiated our Phase 2b clinical study that is designed to examine the efficacy and safety of NUZYRA in patients with M. abscessus pulmonary disease.
Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021 2021/08/09 20:05:00 Intrado Digital Media
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter
Drug-resistant bacteria pose a growing threat. Can new antibiotics be developed fast enough to combat them? 2021/06/22 08:55:36 STAT News
The marketplace is fragile and failing, said Evan Loh, chief executive officer at Paratek Pharmaceuticals.
Why Paratek Pharmaceuticals Stock Is Sinking Today 2021/06/16 16:29:43 The Motley Fool
The company reduced its 2021 revenue outlook.
Paratek Pharmaceuticals To Initiate Clinical Trial Sites For Phase 2b Study Of NUZYRA - Quick Facts 2021/06/16 12:05:41 Business Insider Markets
(RTTNews) - Biopharmaceutical company Paratek Pharmaceuticals, Inc. (PRTK) announced Wednesday the initiation of clinical trial sites for its Phase 2b study exploring the potential utility of Nuzyra (omadacycline) as a treatment for Nontuberculous Mycobacterial (NTM) pulmonary disease caused by mycobacterium abscessus complex (MABc).
Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial 2021/06/16 11:54:19 Seeking Alpha
Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA (omadacycline) 2021/06/16 11:30:00 Wallstreet:Online
-- U.S.-Based Sites Ready to Begin Enrolling Patients, Placebo-Controlled Study Evaluating NUZYRA Efficacy at 12 Weeks of Treatment -- Potential $1.0 Billion Addressable Market Opportunity in the U.S. Based on Company Estimates -- Paratek Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on NTM abscessus today, June 16, 2021 at 10:00am
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs 2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group 2021/01/04 22:00:00 GlobeNewswire
Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc.
Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Sells $127,442.15 in Stock 2020/12/18 14:04:41 Watchlist News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Michael Bigham sold 18,337 shares of the company’s stock in a transaction on Friday, December 11th. The shares were sold at an average price of $6.95, for a total transaction of $127,442.15. Following the transaction, the chairman now owns 572,580 shares of the company’s stock, valued at $3,979,431. The transaction […]
Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Sells $174,882.73 in Stock 2020/12/18 12:14:41 Watchlist News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Michael Bigham sold 26,063 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, December 14th. The shares were sold at an average price of $6.71, for a total transaction of $174,882.73. Following the sale, the chairman now directly owns 572,580 shares in the company, valued at approximately […]
William M. Haskel Sells 4,814 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock 2020/12/16 12:38:41 Watchlist News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 4,814 shares of the business’s stock in a transaction dated Friday, December 11th. The stock was sold at an average price of $6.95, for a total transaction of $33,457.30. Following the sale, the general counsel now owns 210,109 shares in the company, valued at $1,460,257.55. […]